SPOTLIGHT -
Genaera Corp. will begin three phase II trials on squalamine, its systemically administered anti-angiogenic drug.
Eyenuk gets greenlight to market AI screening system in European Union
Commercial real estate and your practice, part two with Colin Carr
Study: Retina specialists gain awareness of biosimilars
Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)
HuidaGene Therapeutics gains FDA clearance for multinational clinical trial of investigational new drug
Foundation Fighting Blindness to kick off PRPH2 and Associated Retinal Diseases Workshop